Rituximab: all 1,386 studies that test it
Page 7 of 14. Open to participants first (177), then studies with results posted, then the rest; newest registration first within each.
- Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT LymphomaCompletedNCT00210353Phase 3Results posted
- Phase II Study of Fludarabine and Mitoxantrone, Followed by GM-CSF(Granulocyte-macrophage Colony-stimulating Factor) and RituximabTerminatedNCT00208975Phase 2Results posted
- Use of Rituximab in Opsoclonus-Myoclonus in Children With NeuroblastomaTerminatedNCT00202930Phase 2Results posted
- Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's LymphomaCompletedNCT00201877Phase 2Results posted
- Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's LymphomaCompletedNCT00193479Phase 2Results posted
- Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHDCompletedNCT00186628Phase 2Results posted
- Doxorubicin (Doxil) Combined With Rituxan, Cyclophosphamide, Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's LymphomasCompletedNCT00184002Phase 2Results posted
- Trial of Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD) in Patients With Relapsed Non-Hodgkins LymphomaCompletedNCT00166439Phase 2Results posted
- Assessment of Rituximab's Immunomodulatory Synovial Effects (The ARISE Study)CompletedNCT00147966Phase 2Results posted
- CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's MacroglobulinemiaTerminatedNCT00142168Phase 2Results posted
- Thalidomide and Rituximab in Waldenstrom's MacroglobulinemiaCompletedNCT00142116Phase 2Results posted
- A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus ErythematosusCompletedNCT00137969Phase 2/3Results posted
- Rituximab and Cyclophosphamide Followed by Vaccine Therapy in Treating Patients With Relapsed Hodgkin LymphomaCompletedNCT00134082Phase 1/2Results posted
- Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or LeukemiaCompletedNCT00133991Phase 2Results posted
- Combination Chemo, Rituximab, and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell LymphomaCompletedNCT00121199Phase 2Results posted
- Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's LymphomaCompletedNCT00117156Phase 2Results posted
- EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell LymphomaCompletedNCT00114738Phase 2Results posted
- Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's LymphomaTerminatedNCT00110149Phase 2Results posted
- CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00109967Phase 2Results posted
- DT PACE, Tandem Autologous Transplant, Maintenance Therapy for Waldenstrom's Macroglobulinemia PatientsTerminatedNCT00107614Phase 2Results posted
- S0433 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Older Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's LymphomaCompletedNCT00107380Phase 2Results posted
- Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM)CompletedNCT00106184Phase 2Results posted
- Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT00104858Phase 2Results posted
- Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic PolyangiitisCompletedNCT00104299Phase 2/3Results posted
- Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell LymphomaCompletedNCT00101010Phase 2Results posted
- Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Primary CNS LymphomaCompletedNCT00098774Phase 2Results posted
- Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic LeukemiaCompletedNCT00098670Phase 2Results posted
- Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202)TerminatedNCT00096460Phase 2/3Results posted
- Lenalidomide With or Without Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaCompletedNCT00096044Phase 2Results posted
- FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed PatientsCompletedNCT00090051Phase 3Results posted
- Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's LymphomaTerminatedNCT00088881Phase 2Results posted
- BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)CompletedNCT00088530Phase 3Results posted
- A Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple SclerosisCompletedNCT00087529Phase 2/3Results posted
- Avastin Plus Rituximab for Patients With B-Cell Non-Hodgkin's LymphomaCompletedNCT00081861Phase 2Results posted
- Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's LymphomaCompletedNCT00078949Phase 3Results posted
- Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus ErythematosusCompletedNCT00076752Phase 2Results posted
- Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's LymphomaCompletedNCT00075946Phase 3Results posted
- Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph CancersTerminatedNCT00074490Phase 2Results posted
- Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLLCompletedNCT00074282Phase 2Results posted
- Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment RegimenTerminatedNCT00074165Phase 2Results posted
- Y 90 Ibritumomab Tiuxetan &Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's LymphomaCompletedNCT00073957Phase 2Results posted
- Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid MalignanciesCompletedNCT00072514Phase 2Results posted
- Rituximab in Treating Patients With Refractory or Relapsed Primary CNS LymphomaTerminatedNCT00072449Phase 2Results posted
- Campath-1H Plus Rituximab for CD52- and CD20- Positive Refractory or Relapsed Chronic Lymphoid DisordersCompletedNCT00071396Phase 2Results posted
- S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's LymphomaCompletedNCT00070018Phase 2Results posted
- Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ TransplantationCompletedNCT00066469Phase 2Results posted
- Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's MacroglobulinemiaTerminatedNCT00060346Phase 2Results posted
- Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell LymphomaCompletedNCT00058422Phase 2Results posted
- Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin LymphomaCompletedNCT00054639Phase 2Results posted
- S0213 Chemotherapy Plus Rituximab in Treating Patients With Mantle Cell LymphomaCompletedNCT00041132Phase 2Results posted
- Chemotherapy and Rituximab With or Without Total-Body Irradiation and Peripheral Stem Cell Transplant in Treating Patients With LymphomaCompletedNCT00039195Phase 2Results posted
- Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's LeukemiaCompletedNCT00039130Phase 2Results posted
- Rituximab to Treat Hepatitis C-Associated Cryoglobulinemic VasculitisCompletedNCT00029107Phase 2Results posted
- Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaTerminatedNCT00012298Phase 1/2Results posted
- S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's LymphomaCompletedNCT00006721Phase 3Results posted
- EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV InfectionCompletedNCT00006436Phase 2Results posted
- Rituximab in Treating Patients With Hodgkin's LymphomaCompletedNCT00003820Phase 2Results posted
- Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients Who Have Chronic Lymphocytic LeukemiaCompletedNCT00003659Phase 2Results posted
- Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression AnalysisCompletedNCT00001586Phase 2Results posted
- Treatment and Natural History Study of Lymphomatoid GranulomatosisCompletedNCT00001379Phase 2Results posted
- Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's LymphomaCompletedNCT00001337Phase 2Results posted
- Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT LymphomaActive, not recruitingNCT07247383Phase 2
- Rituximab for the Treatment of New-onset AChR-Myasthenia GravisActive, not recruitingNCT07071246Not applicable
- Rituximab and Targeted Nursing for Pediatric Nephrotic SyndromeCompletedNCT07049172Not applicable
- Rituximab Therapy in Patients With Treatment Refractory Hypersenstivity PneumonitisCompletedNCT07035561Phase 2
- Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic LeukemiaSuspendedNCT06738368Phase 2
- Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)Active, not recruitingNCT06647732Phase 2
- Phase I Study Evaluating Tolerability, Safety, Pharmacokinetics, and Efficacy of Combined ONO-4059 and R-MPV Therapy for PCNSLActive, not recruitingNCT06541665Phase 1
- GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell LymphomaActive, not recruitingNCT06522386Phase 2
- A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell LymphomaActive, not recruitingNCT06508658Phase 3
- Study for Participants With Relapsed/Refractory Non-Hodgkin LymphomaActive, not recruitingNCT06334991Phase 1
- Rituximab in Chronic Inflammatory Demyelinating PolyradiculoneuropathyCompletedNCT06325943Phase 3
- Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaWithdrawnNCT06247540Phase 2
- Recapturing Immune Tolerance to Pegloticase for the Management of Tophaceous GoutCompletedNCT06186219Phase 1
- Study, Evaluating Pharmacokinetics, Pharmacodynamics, Immunogenicity and Safety Profiles of Rituximab Compared to MabThera® in Patients With Rheumatoid ArthritisActive, not recruitingNCT06175338Phase 1
- Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-DiseaseSuspendedNCT06046248Phase 2
- Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for HypophosphatasiaWithdrawnNCT06015750Phase 4
- Rituxmab Versus IL-6 in Treating ILDCompletedNCT05963048Phase 2/3
- A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell LymphomaActive, not recruitingNCT05951959Phase 2
- Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell LymphomaCompletedNCT05940064Phase 2
- An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell LymphomaWithdrawnNCT05929716Phase 2
- Clinical Study of Rituximab for the Treatment for Idiopathic Membranous Nephropathy With Nephrotic SyndromeActive, not recruitingNCT05914155Phase 3
- A Proof of Concept Study With Rituximab in Patients With CIDP Not Responding to Conventional Immune TherapyActive, not recruitingNCT05877040Phase 2
- A Randomized, Controlled Clinical Study of Rituximab in Treatment of Primary IgA NephropathyStatus unknownNCT05824390Phase 4
- Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOPActive, not recruitingNCT05798156Phase 2
- R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaStatus unknownNCT05784987Not applicable
- Efficacy of Rituximab Combined With Cyclosporine in the Treatment of Idiopathic Membranous NephropathyStatus unknownNCT05782933Not applicable
- R-CMOP in Patients With Primary Diffuse Large B-cell LymphomaStatus unknownNCT05777369Not applicable
- First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228Active, not recruitingNCT05737628Phase 1
- A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular LymphomaActive, not recruitingNCT05683171Phase 1/2
- A Randomized Controlled Trial With Rituximab for Psychotic Disorder in AdultsActive, not recruitingNCT05622201Phase 2
- Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell LymphomaActive, not recruitingNCT05600686Phase 2
- Immunomodulatory Therapy in Women With Autoimmune Premature Ovarian InsufficiencyCompletedNCT05586737Phase 2
- A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular LymphomaActive, not recruitingNCT05551936Phase 1/2
- Orelabrutinib,Rituximab and Methotrexate in Newly-diagnosed Primary Central Nervous System Lymphoma(PCNSL)Status unknownNCT05549284Phase 2
- Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Experiencing a PMR RelapseActive, not recruitingNCT05533164Phase 3
- Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Recently DiagnosedCompletedNCT05533125Phase 3
- A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell LymphomaActive, not recruitingNCT05495464Early Phase 1
- Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic SyndromeActive, not recruitingNCT05457556Phase 3
- Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic LeukemiaActive, not recruitingNCT05453500Phase 2